>MDVN PFE ELN WYE etc. – Dimebon became the clear Alzheimer front-runner at ICAD after they showed effectiveness in trials not run by sketchy Russians.<
I posted the Dimebon PR on the iHub ELN board and it was promptly deleted by one of the moderators as “off topic.” Go figure.
MDVN – An interesting tidbit on the Dimebon deal: PFE’s pre-deal DD put 25 executives to work for six months and included trips to Russia (where Dimebon is approved as an antihistamine).
Even for a company as large as PFE, $225M in up-front cash and $500M in regulatory milestones is serious money.
Market Data 
Markets 
AI
